Research Xchange Forum 2018

Similar documents
Research Xchange Forum 2018

Research Xchange Forum Insights Translation Solutions. Agenda February 2017 Sartorius College Goettingen, Germany

Advancing Manufacturing for Advanced Therapies

Adoptive cellular therapies are based on the administration of live cells into a patient in order for them to serve a therapeutic purpose.

Whitepaper. Small Molecule Vs Cell Therapy Clinical Trial Supply Chain. Martin Lamb, Executive Vice President for Sales and Marketing

Course Agenda. Day One

Webinar: CAR-T Approval: What s Next

NMI Natural and Medical Sciences Institute at the University of Tübingen

ABOUT GLYCOSTEM. Company Overview

Stem Cell Research: Identifying emerging high priority policy issues

Immuno-Oncology Program

Cell & Stem Cell Research

REPORT ON 2 nd BWC. 6. Regenerative Medicine: stem cells, gene therapy; tissue engineering; cell based therapy; cell cultivation.

Unicyte AG, regenerative medicine unit of Fresenius Medical Care, appoints world-leading experts to Scientific Advisory Board

to precision medicine

First Quarter Trusted by the Life Sciences Industry

29th - 30th May 2018 Dorint Hotels and Resorts, Main Taunus Zentrum, Frankfurt, Germany

Navigating the Manufacturing Process and Assuring the Quality of Regenerative Medicine Therapies A Workshop

CAR-T Cells enter center stage!

Tissue Science Congress 2018

Scale-Up and Manufacturing of Cell-Based Therapies III

Exceptions for inventions involving the treatment of humans. James Love, KEI

(212) Cellectis Media Contact: Philippe Valachs +33(0)

Transforming Cancer Research through Cell Authentication

DOP Annual Conference 2018

Regulatory Perspectives on Gene Therapies for Rare Diseases Rare Diseases Forum Washington, D.C. October 17, 2018

CBER Regulatory Updates: Initiatives for Product Review and Licensure

Exploring Sources of Variability Related to the Clinical Translation of Regenerative Engineering Products A Workshop

Stem Cell and Regenerative Medicine 50+ B2B Meetings. conferenceseries.com. 10 th Annual Conference on. August 13-14, 2018 London, UK

Translational Research through Public-Private Partnerships. 65 th Annual Bohan Lecture. Scott J. Weir, PharmD, PhD 08 October 2011

Outcomes in Mesenchymal Stem Cell Manufacturing. Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL

Biological & Pharmaceutical Sciences July 12-13, 2019 Yokohama, Japan

CMC Considerations for Manufacturing of CAR T-Cell Product

The Cell and Gene Therapy Catapult UK clinical trials database

Regulatory Pathways for Rare Diseases

Re: National Coverage Analysis (NCA) Tracking Sheet for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451N)

Our job today Enlist you to help us cross the Translational Divide between the lab bench and the patient s bedside Demonstrate that this will

PACT. PACT Program. Production Assistance for Cellular Therapies

Regenerative Medicine and Stem Cell Therapies

NETWORKING AND CUREACCELERATOR LIVE!

STEM CELL AND REGENERATIVE MEDICINE. Cell in Progress: Exploring Regenerative medicine through Stem Cells

Recent years have witnessed an expansion in the disciplines encompassing drug

International Conference of the Korean Society for Molecular and Cellular Biology

Sangamo Therapeutics Announces Presentations at 2017 Annual meeting of the American Society of Gene & Cell Therapy

A gateway to academic excellence for Biotech and Pharma

Clinical Development of Gene Therapy: Safety Evaluation and Monitoring

Important Upcoming BioNJ Events

A GATEWAY TO ACADEMIC EXCELLENCE FOR BIOTECH AND PHARMA

4 th International Advanced ICAS Training Course on "Blood Stem Cell Transplantation: State of the Arts, Methods, Perspectives" April 2007

Assessing and Controlling Potency of Vector and Drug Product for Chimeric Antigen Receptor T Cells

KEYNOTESPEAKERS. JamesWilson ProfessorofInternalMedicineandPathology& LaboratoryMedicineand DirectoroftheGeneTherapyProgram UniversityofPennsylvania

Re: Public Consultation Paper on the Regulation of Advanced Therapy Medicinal Products

ENGINEERED CAR-T THERAPIES

Cell and gene therapy: scaling up and moving to mass production

Q4 and Full Year 2017 Conference Call. February 22, 2018

EUROPEAN MEMS & SENSORS SUMMIT 2018

3D & SYSTEMS SUMMIT 2019

Geneva. Call for Abstracts, Registration and Accommodation Brochure. 9th International Conference on New Trends in Immunosuppression & Immunotherapy

European Regenerative Medicine Firms & Their Strategic Approaches. Michael Morrison University of York

Clinical Policy: Tisagenlecleucel (Kymriah) Reference Number: CP.CPA.XX Effective Date: Last Review Date: Line of Business: Commercial

EVENT DETAILS WHO WE ARE WHAT TO EXPECT WHO ATTENDS ATTENDANCE INFORMATION EXHIBITOR BENEFITS SPONSORSHIP PACKAGES OUR GOALS MEDIA STRATEGY CONTACT US

Antibody Discovery at Evotec

Eleventh Annual Chapel Hill Pharmaceutical Sciences Conference. Pharmacy in the Era of Precision Medicine: From Discovery to Implementation

Brochure. 3 rd International Conference on Applied Microbiology and Beneficial Microbes. June Osaka, Japan. conferenceseries.

APRIL 25, 2019 GILEAD SCIENCES, INC. OCEANSIDE

of Innovative Pharmaceuticals* and Takao Inoue 4

Protein & Biomedical Engineering

PROGRAMME T

Proteomics & Bioinformatics

Des cellules-souches dans le poumon : pourquoi faire?

Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing

GENERATION OF OFF-THE-SHELF TCR-LESS CAR T CELLS FROM RENEWABLE PLURIPOTENT CELLS

Press Release. Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies

Personalised Medicine Regulatory Issues

WELCOME AND STATE OF THE INDUSTRY REMARKS. Janet Lynch Lambert. CEO, Alliance for Regenerative Medicine

EVENT DETAILS WHEN. Workshops 29th September

2016 Partnership Marketing Sponsorship Opportunities

The Cell and Gene Therapy Catapult UK clinical trials database

SCM Lifescience COMPANY PROFILE BUSINESS AREAS. [Address] 310, 366 Seohae-daero, Jung-gu, Incheon, Korea [Website]

DOP Annual Conference January - Crowne Plaza, Chester. Thriving at work. Sponsorship and Exhibition Opportunities

This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform

Stem Cells: Introduction and Prospects in Regenerative Medicine.

The NYSCF Research Institute

Temperature Controlled Distribution of Biologics. September 11 th 2018 The Alexandria at Torrey Pines, San Diego.

Brochure. Medical Nanotechnology Congress. September 03-04, 2018 Tokyo, Japan. conferenceseries.com. 16 th World. Conference Secretariat

An Overview of Chimeric Antigen Receptor T-cells: CAR-T-ing Away Cancer

EMA s role & responsibility for the development of modern/advanced therapies

20 th Asia Pacific Nanotechnology Congress

Realizing the Future that Regenerative Medicine Will Open

Research Xchange Forum 2019

Important Upcoming BioNJ Events

Biomarkers and Patient s Access to Personalized Oncology Drugs in Europe

STEM CELLS AND REGENERATIVE MEDICINE GLOBAL SUMMIT AT A GLANCE. The Summit. Spearheading Stem Cell Innovations

Where BioPharma stakeholders

Biotechnology and Health Care

TRIANNI Media Kit MEDIA CONTACT CORPORATE HEADQUARTERS. Trianni, Inc. San Francisco, CA

Production Assistance for Cellular Therapies PACT

HUMAN GENETICS AND GENETIC DISEASES

NEXT-GENERATION CAR T-CELLS AGAINST CANCER. Gene-Edited Off-The-Shelf Immunotherapies

SPONSORSHIP OPPORTUNITIES

Transcription:

Research Xchange Forum 2018 Insights Translation Solutions Trends and Challenges in Regenerative Medicine & Cell Therapy March 20 21, 2018 Sartorius Goettingen, Germany

What to expect Learn about the latest Insights in regenerative medicine and cell therapy and exchange ideas as to their Translation into viable Solutions. Our Research Xchange Forum brings together academic and industry experts to foster exchange and to stimulate dialog about the next generation of interdisciplinary research. Establish new contacts and explore the potential for collaborations with like- minded companies and academic professionals to gain a better understanding of their processes, workflows and challenges. Deepen your discussions during a joint gala dinner and be there when the winner and the 3 finalists of The Sartorius & Science Prize for Regenerative Medicine & Cell Therapy receive their awards. Winner: U.S. $25,000 + publication in Science print and online; 3 finalists: U.S. $5,000 per winner + publication in Science online. We look forward to seeing you at our Research Xchange Forum.

Highlights l Keynote lectures by the winner and lectures by the 3 finalists of The Sartorius & Science Prize for Regenerative Medicine & Cell Therapy, including a speech by Science editor Dr. Priscilla N. Kelly l Keynote lectures on cellular immunotherapy by industry experts l Inspirational speech by the Nobel Prize laureate of 2014 in chemistry Prof. Dr. Stefan W. Hell l Panel discussion with stakeholders from industry and academia including Science editor Dr. Priscilla N. Kelly l Gala dinner and award ceremony for the exceptional scientists receiving The Sartorius & Science Prize for Regenerative Medicine & Cell Therapy l Thought-provoking dialog and networking opportunities with academic and industry experts l Exclusive inside view into the work processes of Sartorius during an optional plant tour Awarded by

Speaker line-up * Guest Contributors Dr. Priscilla N. Kelly, Washington DC, USA AAAS/Science Editor Topic: How to publish in Science Peter Badge/ Typos1 in cop. with Foundation Lindau Nobel Laureate Meetings all rights reserved 2017. Prof. Dr. Stefan W. Hell, Goettingen, Germany Max Planck Institute for Biophysical Chemistry Managing Director and Nobel Prize laureate of 2014 in chemistry Topic: How to win a Nobel Prize

Academic Speakers Keynote lecture by the winner and lectures by the 3 finalists of The Sartorius & Science Prize for Regenerative Medicine & Cell Therapy Prof. Dr. Stefan Wölfl Heidelberg, Germany University of Heidelberg, Institute for Pharmacy and molecular Biotechnology Topic: Small molecules to enable, faciliate and improve ipsc generation and cell reprogramming Overview: The generation of patient specific specialized cell-types is a major task in regenerative medicine. Despite the success of genetic reprogramming protocols, it is still a challenge to generate, cultivate and expand patient specific induced pluripotent stem cells (ipscs). The generation of ipscs requires the expression of specific transcription factors, expression of which is maintained to conserve the pluripotent state. For reprogramming these factors are inhibited and tissue specific sets of gene expression are induced. We focus on the development of chemical compounds to replace genetic reprogramming and e.g. have identified Oct4 inducing small molecules. Although we cannot yet fully replace genetic reprogramming factors, our small molecules improve reprogramming efficiency, overcome reprogramming resistance and improve cultivation of ipscs for reprogramming. *subject to change

Speaker line-up * Industry Speakers Dr. Ulf Geumann, Munich, Germany apceth Biopharma GmbH, Group Leader Preclinical Development Topic: Mesenchymal stem cells in immunotherapy Overview: apceth is harnessing the potential of mesenchymal stem cells (MSC), in which the mechanism of therapeutic effects are very different from that of CAR-T cells. The aim is to provide innovative cell-based gene therapies for the treatment of major indications such as cancer, chronic lung and kidney diseases and for immuno modulation. apceth has created its allogenic therapeutic platform based entirely on the genetic engineering of MSC isolated from healthy donors. Francesca Bellintani, Milan, Italy MolMed, Vector Downstream Process Development Manager Topic: Retroviral and lentiviral production: development and scaling up of upstream and downstream process steps Overview: MolMed has implemented a large-scale process to meet the increasing demand for clinical and commercial grade vector production. There is a special focus on identification of challenges in the downstream purification strategy to ensure efficient contaminant removal and preservation of viral infectivity. *subject to change

Dr. Thierry Wurch Suresnes, France Servier, Director of External Studies in Immuno-oncology Topic: Allogenic approach developed by Servier and the preclinical data of UCART19 Overview: Servier is applying the Cellectis TALEN gene editing technology to overcome current limitations and provide an allogeneic, frozen, off-the-shelf T cell based medicinal product. UCART19 is an allogeneic CAR T-cell product candidate being developed for treatment of CD19-expressing hematological malig nancies. It is currently being evaluated in a phase 1 clinical trials in relapsed refractory acute lymphoblastic leukemia (ALL) of adult and pediatric patients. The selection of UCART19 as a candidate was based on the impressive clinical benefits leading to the marketing of the two first autologous CAR T-cell products Kymriah (Novartis) and Yescarta (Kite Gilead). Dr. Nina G. Bauer Basel, Switzerland Lonza Assoc. Director of Commercial Development, Autologous Cell Therapies Topic: Manufacturing strategies for patient scale cell therapies Overview: The Future Technologies business area under the Pharma & Biotech division of Lonza has a focus on personalized medicine & cell therapy. One of the major challenges in these fields is the production of the patient-specific and patient- scale CAR-T cells or stem cells for treatment. Lonza has partnered with Octane on the Octane Cocoon platform, which offers a ground- breaking innovation to address this challenge. Unlike current, labor-intensive production methods, this platform has the potential to enable the automated manufacturing of patient-specific cell therapies for maximum efficiency, traceability and scale-up.

Agenda Tuesday, March 20 Chair: Ruth McDermott 09:40 Transfer to Sartorius College (from hotel) 10:00 11:00 Registration 11:00 11:30 Welcome & Introduction Gerry MacKay, Sartorius, Germany Member of the Group Executive Commitee and Executive Vice President LPS Marketing Sales Services 11:30 12:00 Inspirational speech: How to win a Nobel Prize Prof. Dr. Stefan Hell, Max Planck Institute for Biophysical Chemistry, Germany Managing Director and Nobel Prize laureate of 2014 in chemistry 12:00 12:30 How to publish in Science Dr. Priscilla N. Kelly, AAAS Science, USA Editor 12:30 13:15 Lunch break Application Session 13:15 14:00 Keynote presentation Sartorius & Science Prize Winner 14:00 14:30 Lecture Sartorius & Science Prize Finalist 1 14:30 15:00 Coffee break 15:00 15:30 Lecture Sartorius & Science Prize Finalist 2 15:30 16:00 Lecture Sartorius & Science Prize Finalist 3

16:00 17:00 Panel Discussion In search of excellence -Scientific publications in the 21 st century 17:00 17:15 Sum up & Closing 17:20 Transfer to hotel (from Sartorius College) 18:15 Transfer to award ceremony (from hotel) 18:30 23:30 Award ceremony 23:30 Transfer to hotel Moderation: Dr. Reinhard Baumfalk, Sartorius, Germany Vice President R&D Instrumentation & Control Participants: Prof. Dr. Stefan Hell, Dr. Priscilla N. Kelly, Dr. Ulf Geumann

Agenda Wednesday, March 21 Chair: Del Trezise 08:15 Transfer to Sartorius College Sartorius Trainingscenter (from hotel) 08:30 10:00 Optional Plant Tour (Sartorius College) or Upscaling Lab Demonstration Tour (Sartorius Trainingscenter) 09:40 Transfer to Sartorius College (from Sartorius Traningscenter) 10:00 10:15 Opening Day 2 10:15 11:00 Manufacturing strategies for patient scale cell therapies Dr. Nina G. Bauer, Lonza, Switzerland Assoc. Director of Commercial Development, Autologous Cell Therapies Dr. Thierry Wurch, Servier, France Director of External Studies in Immuno-oncology 11:00 11:30 Allogenic approach development by Servier and the preclinical data of UCART19 11:30 12:30 Lunch break Application & Poster Session 12:30 13:00 Small molecules to enable, faciliate and improve Prof. Dr. Stefan Wölfl University Heidelberg, Germany ipsc generation and cell reprogramming Institute for Pharmacy and molecular Biotechnology 13:00 13:30 Mesenchymal stem cells in immunotherapy Dr. Ulf Geumann, apceth Biopharma GmbH, Germany Group Leader Preclinical Development 13:30 14:00 Retroviral and lentiviral production: development and Dr. Francesca Bellintani, MolMed, Italy scaling up of upstream and downstream process steps Vector Downstream Process Development Manager 14:00 14:10 Sum up & Closing

Registration March 20 21, 2018 To register and to obtain further information, please visit our website: promotions.sartorius.com/rxf2018 The registration fee includes admission, gala dinner, all coffee breaks, lunches and the optional plant tour. Advance registration is required. We offer an early bird discount until January 15, 2018 Industry Business Academia PhD Students Students Early Bird 395 EUR 295 EUR 105 EUR Regular 595 EUR 495 EUR 195 EUR Group Ticket Pay the 1st ticket and get 50% off for every additional registration Venue: Sartorius College Otto Brenner Strasse 20 37079 Goettingen, Germany www.sartorius.com Your Contact: Romi Jeromis Sartorius Lab Instruments GmbH & Co. KG Phone: +49.551.308.2659 forum@sartorius.com If you have any questions, just contact us at any time we would be happy to help you. Please note that photos and videos will be taken during the event. If you do not wish to be photographed, please let us know upon registration. Follow us on Twitter #rxf2018

Research Xchange Forum 2018 Get insights into the latest developments from internationally renowned academic and industry speakers. Special Section: Lectures from The Sartorius & Science Prize for Regenerative Medicine & Cell Therapy Winner and Finalists. March 20 21, 2018 Register now! To register and to obtain further information, please visit our website: promotions.sartorius.com/rxf2018 Awarded by Sartorius Lab Instruments GmbH & Co. KG Otto-Brenner-Strasse 20 37079 Goettingen